Walleye Capital
ESPR

Walleye Capital’s Esperion Therapeutics ESPR Stock Holding History

Walleye Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,031
Closed -$8.3K – 4859
2026
Q1 		$8.3K Sell
3,031
-1,566,185
-100% -$4.96M ﹤0.01% 4173
2025
Q4 		$5.81M Buy
1,569,216
+1,250,025
+392% +$4.04M 0.02% 1035
2025
Q3 		$846K Buy
+319,191
New +$617K ﹤0.01% 2222
2025
Q1 		– Sell
-80,837
Closed -$178K – 4475
2024
Q4 		$178K Buy
+80,837
New +$189K ﹤0.01% 3846
2024
Q2 		– Sell
-227,630
Closed -$610K – 5699
2024
Q1 		$610K Buy
227,630
+13,630
+6% +$33.1K ﹤0.01% 3023
2023
Q4 		$640K Buy
+214,000
New +$278K ﹤0.01% 2746
2023
Q2 		– Sell
-12,296
Closed -$19.6K – 4464
2023
Q1 		$19.6K Buy
+12,296
New +$63.5K ﹤0.01% 3406
2022
Q4 		– Sell
-698,343
Closed -$4.68M – 3305
2022
Q3 		$4.68M Sell
698,343
-26,111
-4% -$179K 0.09% 247
2022
Q2 		$4.61M Buy
724,454
+417,773
+136% +$2.37M 0.13% 190
2022
Q1 		$1.42M Buy
306,681
+145,932
+91% +$626K 0.04% 479
2021
Q4 		$804K Buy
+160,749
New +$1.29M 0.03% 713
2020
Q1 		– Sell
-300
Closed -$18K – 1147
2019
Q4 		$18K Buy
+300
New +$13.5K ﹤0.01% 1614
2019
Q3 		– Sell
-529
Closed -$21K – 1984
2019
Q2 		$25K Buy
+529
New +$24.8K ﹤0.01% 1498

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Walleye Capital's ESPR Position: Q2 2026 in Review

Walleye Capital sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 3,031 shares — an estimated $8.3K sold.

Walleye Capital first reported a position in ESPR in Q2 2019 and held it in 13 quarters. The position peaked at $5.81M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Walleye Capital reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 3,031 Esperion Therapeutics shares in Q2 2026, an estimated $8.3K.
  • Walleye Capital first reported a position in Esperion Therapeutics in Q2 2019 and held it in 13 quarters.
  • Walleye Capital's Esperion Therapeutics position peaked at $5.81M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.